Vascular Protective Effects Of Pushen Capsules On Hypertriglyceridemia

Objective: Follow the continuous changes of vascular injury, exploratory select8weeks,12weeks,16weeks as the treatment of node. Observe how Pushen capsuleinfluence vascular inflammatory cytokines (hsCRP) and endothelial secretion of activefactors (eNOS and ET-1), the earlier and late stage arterial stiffness/brachial-ankle pulsewave velocity (baPWV), Early blood flow-dependent vasodilation response (FMD). Inorder to evaluate the protective effect Of Pushen capsules on the vascular endothelialfunction, vascular elasticity and structural changes in every curing node.Methods: We selected50patients who come from Plain County, Shandong Province,on the county education system serving and retired people. All of them hadhypertriglyceridemia associated with endothelial dysfunction that met the inclusioncriteria.They were randomly divided into traditional test group(n=33) which were givenPushen capsules for16weeks, and the control group (n=17) which were given acipimoxfor16weeks. Detect the indicators in each patient before treatment. And after8weeks oftreatment, fasting blood samples were collected for routine measurement of serum lipids(TC, TG, LDL-C, HDL-C), immunoturbidimetric assay hsCRP, double antibody sandwichELISA measurements eNOS and ET-1. After12weeks of treatment, did the non-invasivedetection of FMD. At the end of16weeks treatment, did non-invasive detection baPWV.Results:1. After8weeks of treatment,the test group can significantly reduce thepatient TG, LDL-C levels (P<0.05), with the control group treatment effect isquite(P>0.05);2. After8weeks treatment, the test group can significantly reduce serumhsCRP levels in patients (P<0.05), a significant difference (P<0.05) compared with thecontrol group; Meanwhile, the test group can significantly elevate the serum levels of eNOS (P<0.05) in treatment patients.And meantime lower levels of ET-1(P<0.05), thereare significant differences (P<0.05) compared with the control group.3. After12weeks oftreatment, the test group can effectively improve FMD values of patients (P<0.05), asignificant difference compared with the control group (P<0.05).4. After16weeks oftreatment, there are no significant changes in the test group with baPWV (P>0.05), butbaPWV levels in the control group increased more higher than the test group (P<0.05).5.Linear correlation analysis shows that TG and ET-1was positively correlated (r=0.968,r=0.953, P=0.000), and eNOS was negatively correlated (r=-0.925and r=-0.936, P=0.000),hsCRP and baPWV showed a significant positively correlation (r=0.960, P=0.000).Conclusion:1. Pushen capsule’s protective effect mostly incarnate in effectivelyreducing the abnormal TG, mitigating lipotoxicity endothelial injury, and preventingEC/NOS/NO pathway damage.2. Pushen capsule’s protective effect began in improvingearly endothelial dysfunction. First, it can effectively reduce hsCRP levels and exert itseffect by adjusting the balance of inflammation and thus affect the process ofatherosclerosis. Second, it can increase eNOS and reducing ET-1, by improving vascularendothelial secretion better to maintain normal vasomotor function.3. Pushen capsule cansignificantly improve the patients’ FMD, with a clear improvement inendothelium-dependent vasodilation function.4. Pushen capsule can delay the vascularelasticity decline in hypertriglyceridemia patients, and thus play greater vascular protectiveeffects.